After A Healthy Correction Can BioMarin Stock Offer Any Upside?
- Monday, September 14, 2020, 7:25
- Market
- Add a comment
The stock price of BioMarin Pharmaceutical, a relatively small pharmaceutical company with a market capitalization of $13 billion, hasn’t seen any growth since late March (vs. about 53% for the S&P 500) and it is still trading at $72. The stock fell 21% from its pre-crisis peak of $90 to a low…
About the Author
admin123 has written 23527 stories on this site.
